Ag-bearing liposomes engrafted with peptides that interact with CD11c/CD18 induce potent Ag-specific and antitumor immunity

International Journal of Cancer

Volumn 129, Issue 6, 2011, Pages 1391-1403

  Faham, Abdus ^a   Altin, Joseph G ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

antitumor response; CD11c; plasma membrane vesicles; stealth liposomes; vaccines

Indexed keywords

CD18 ANTIGEN; GLYCOPROTEIN P 15095; IMMUNOLIPOSOME; INTERCELLULAR ADHESION MOLECULE 4; PEPTIDE; PROTEIN P17; PROTEIN P18; PROTEIN P30; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; LUNG METASTASIS; MEMBRANE VESICLE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD11; ANTIGENS, CD18; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL MEMBRANE STRUCTURES; DENDRITIC CELLS; FEMALE; LIPOSOMES; MICE; MICE, INBRED C57BL; OVALBUMIN; VACCINES, SUBUNIT;

EID: 79960924004     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25810     Document Type: Article

References (37)

1. Banchereau J, Palucka AK,. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306. (Pubitemid 40516155)
2. Fajardo-Moser M, Berzel S, Moll H,. Mechanisms of dendritic cell-based vaccination against infection. Int J Med Microbiol 2008; 298: 11-20. (Pubitemid 350216547)
3. Sadhu C, Ting HJ, Lipsky B, Hensley K, Garcia-Martinez LF, Simon SI, Staunton DE,. CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity. J Leukoc Biol 2007; 81: 1395-403. (Pubitemid 46827962)
4. Reddy ST, Swartz MA, Hubbell JA,. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006; 27: 573-9. (Pubitemid 44708833)
5. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S,. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-67. (Pubitemid 34293436)
6. Proudfoot O, Apostolopoulos V, Pietersz GA,. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol Pharm 2007; 4: 58-72.
7. Balkow S, Loser K, Krummen M, Higuchi T, Rothoeft T, Apelt J, Tuettenberg A, Weishaupt C, Beissert S, Grabbe S,. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Exp Dermatol 2009; 18: 78-87.
8. van Broekhoven CL, Altin JG,. A novel approach for modifying tumor cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumor immunotherapy. Int J Cancer 2002; 98: 63-72. (Pubitemid 34113420)
9. Altin JG, van Broekhoven CL, Parish CR,. Targeting dendritic cells with antigen-containing liposomes: antitumor immunity. Expert Opin Biol Ther 2004; 4: 1735-47. (Pubitemid 39518107)
10. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM,. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199: 815-24. (Pubitemid 38375201)
11. Castro FV, Tutt AL, White AL, Teeling JL, James S, French RR, Glennie MJ,. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol 2008; 38: 2263-73.
12. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG,. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64: 4357-65. (Pubitemid 38802444)
13. Eichler J,. Peptides as protein binding site mimetics. Curr Opin Chem Biol 2008; 12: 707-13.
14. An P, Lei H, Zhang J, Song S, He L, Jin G, Liu X, Wu J, Meng L, Liu M, Shou C,. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Cancer 2004; 111: 165-73. (Pubitemid 38924692)
15. Chamarthy SP, Jia L, Kovacs JR, Anderson KR, Shen H, Firestine SM, Meng WS,. Gene delivery to dendritic cells facilitated by a tumor necrosis factor alpha-competing peptide. Mol Immunol 2004; 41: 741-9. (Pubitemid 38953631)
16. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, Hoffman RM, Ruoslahti E,. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 2004; 101: 9381-6. (Pubitemid 38812883)
17. Maruta F, Parker AL, Fisher KD, Hallissey MT, Ismail T, Rowlands DC, Chandler LA, Kerr DJ, Seymour LW,. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther 2002; 9: 543-52. (Pubitemid 34569037)
18. Metlay JP, Witmer-Pack MD, Agger R, Crowley MT, Lawless D, Steinman RM,. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med 1990; 171: 1753-71. (Pubitemid 20167564)
19. Brocker T, Riedinger M, Karjalainen K,. Driving gene expression specifically in dendritic cells. Adv Exp Med Biol 1997; 417: 55-7. (Pubitemid 27427719)
20. Kotovuori A, Pessa-Morikawa T, Kotovuori P, Nortamo P, Gahmberg CG,. ICAM-2 and a peptide from its binding domain are efficient activators of leukocyte adhesion and integrin affinity. J Immunol 1999; 162: 6613-20. (Pubitemid 29309385)
21. Ihanus E, Uotila LM, Toivanen A, Varis M, Gahmberg CG,. Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4. Blood 2007; 109: 802-10. (Pubitemid 46105985)
22. Frick C, Odermatt A, Zen K, Mandell KJ, Edens H, Portmann R, Mazzucchelli L, Jaye DL, Parkos CA,. Interaction of ICAM-1 with beta 2-integrin CD11c/CD18: characterization of a peptide ligand that mimics a putative binding site on domain D4 of ICAM-1. Eur J Immunol 2005; 35: 3610-21. (Pubitemid 43025541)
23. Altin JG, Banwell MG, Coghlan PA, Easton CJ, Nairn MR, Offermann DA,. Synthesis of NTA3-DTDA-a chelator-lipid that promotes stable binding of his-tagged proteins to membranes. Aust J Chem 2006; 59: 302-6. (Pubitemid 43877055)
24. van Broekhoven CL, Altin JG,. The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells. Biochim Biophys Acta 2005; 1716: 104-16. (Pubitemid 41532288)
25. Herringson TP, Patlolla RR, Altin JG,. Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J Gene Med 2009; 11: 1048-63.
26. Van Broekhoven CL, Altin JG,. A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. Immunol Cell Biol 2001; 79: 274-84. (Pubitemid 32522176)
27. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM,. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693-702.
28. Faham A, Bennett D, Altin JG,. Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumor immunity. Vaccine 2009; 27: 5846-54.
29. Kurts C,. CD11c: not merely a murine DC marker, but also a useful vaccination target. Eur J Immunol 2008; 38: 2072-5.
30. Shortman K, Liu YJ,. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2: 151-61. (Pubitemid 37336516)
31. Corbi AL, Garcia-Aguilar J, Springer TA,. Genomic structure of an integrin alpha subunit, the leukocyte p150,95 molecule. J Biol Chem 1990; 265: 2782-8.
32. Lee JO, Bankston LA, Arnaout MA, Liddington RC,. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure 1995; 3: 1333-40. (Pubitemid 3012265)
33. Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA,. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol 1993; 120: 1031-43. (Pubitemid 23056308)
34. Choi J, Nham SU,. Loops within the CD11c I domain critical for specific recognition of fibrinogen. Biochem Biophys Res Commun 2002; 292: 756-60. (Pubitemid 34681123)
35. Wang H, Griffiths MN, Burton DR, Ghazal P,. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA 2000; 97: 847-52. (Pubitemid 30070398)
36. Berry JD, Licea A, Popkov M, Cortez X, Fuller R, Elia M, Kerwin L, Kubitz D, Barbas CF, 3rd,. Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybrid Hybridomics 2003; 22: 23-31. (Pubitemid 36458233)
37. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA, Davey GM, Wilson NS, Carbone FR, Villadangos JA,. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199: 9-26. (Pubitemid 38736761)